Abliva AB (publ) (ABLI.ST)
SEK 0.42
(-0.83%)
SEK 0.42
(-0.83%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -35.66 Million SEK | 58.0% |
| 2022 | -84.9 Million SEK | -162.39% |
| 2021 | -32.35 Million SEK | -0.46% |
| 2020 | -32.2 Million SEK | -2.39% |
| 2019 | -31.45 Million SEK | 3.43% |
| 2018 | -32.57 Million SEK | -0.32% |
| 2017 | -32.47 Million SEK | 15.76% |
| 2016 | -38.55 Million SEK | 23.52% |
| 2015 | -50.4 Million SEK | -44.81% |
| 2014 | -34.81 Million SEK | -104.09% |
| 2013 | -17.05 Million SEK | -43.81% |
| 2012 | -11.86 Million SEK | -313.46% |
| 2011 | 5.55 Million SEK | 60.91% |
| 2010 | 3.45 Million SEK | -22.11% |
| 2009 | 4.43 Million SEK | 387.83% |
| 2008 | 908.66 Thousand SEK | 0.0% |
| 2007 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -490 Thousand SEK | -1.03% |
| 2024 Q1 | -485 Thousand SEK | 93.95% |
| 2023 Q2 | -714 Thousand SEK | -0.42% |
| 2023 FY | -35.66 Million SEK | 58.0% |
| 2023 Q1 | -711 Thousand SEK | -1.57% |
| 2023 Q3 | -8.52 Million SEK | -1093.28% |
| 2023 Q4 | -8.01 Million SEK | 5.95% |
| 2022 Q2 | -7.59 Million SEK | -1148.36% |
| 2022 FY | -84.9 Million SEK | -162.39% |
| 2022 Q4 | -700 Thousand SEK | 89.68% |
| 2022 Q1 | -608 Thousand SEK | 98.36% |
| 2022 Q3 | -6.78 Million SEK | 10.61% |
| 2021 Q1 | -658 Thousand SEK | 94.21% |
| 2021 Q3 | -11.34 Million SEK | -18.92% |
| 2021 Q4 | -36.99 Million SEK | -226.23% |
| 2021 FY | -32.35 Million SEK | -0.46% |
| 2021 Q2 | -9.53 Million SEK | -1349.24% |
| 2020 Q3 | -6.69 Million SEK | 57.59% |
| 2020 FY | -32.2 Million SEK | -2.39% |
| 2020 Q4 | -11.35 Million SEK | -69.55% |
| 2020 Q2 | -15.79 Million SEK | -32.16% |
| 2020 Q1 | -11.94 Million SEK | 48.96% |
| 2019 FY | -31.45 Million SEK | 3.43% |
| 2019 Q3 | -11.59 Million SEK | 31.24% |
| 2019 Q1 | -9.63 Million SEK | 32.99% |
| 2019 Q4 | -23.41 Million SEK | -101.94% |
| 2019 Q2 | -16.86 Million SEK | -75.09% |
| 2018 Q3 | -11.21 Million SEK | 43.12% |
| 2018 Q2 | -19.71 Million SEK | -117.94% |
| 2018 Q1 | -9.04 Million SEK | 23.59% |
| 2018 FY | -32.57 Million SEK | -0.32% |
| 2018 Q4 | -14.37 Million SEK | -28.11% |
| 2017 FY | -32.47 Million SEK | 15.76% |
| 2017 Q4 | -11.84 Million SEK | -21.35% |
| 2017 Q3 | -9.75 Million SEK | 46.02% |
| 2017 Q2 | -18.07 Million SEK | -169.58% |
| 2017 Q1 | -6.7 Million SEK | 31.89% |
| 2016 FY | -38.55 Million SEK | 23.52% |
| 2016 Q1 | -7.37 Million SEK | -92.06% |
| 2016 Q4 | -9.84 Million SEK | -7.35% |
| 2016 Q3 | -9.17 Million SEK | -18.24% |
| 2016 Q2 | -7.75 Million SEK | -5.12% |
| 2015 Q3 | -19.68 Million SEK | -67.79% |
| 2015 FY | -50.4 Million SEK | -44.81% |
| 2015 Q4 | -3.84 Million SEK | 80.48% |
| 2015 Q1 | - SEK | 100.0% |
| 2015 Q2 | -11.73 Million SEK | 0.0% |
| 2014 Q2 | -12.35 Million SEK | 0.0% |
| 2014 FY | -34.81 Million SEK | -104.09% |
| 2014 Q1 | - SEK | 100.0% |
| 2014 Q4 | -12.61 Million SEK | -1160.44% |
| 2014 Q3 | -1 Million SEK | 91.9% |
| 2013 Q4 | -6.7 Million SEK | -27.51% |
| 2013 FY | -17.05 Million SEK | -43.81% |
| 2013 Q3 | -5.25 Million SEK | -1380.56% |
| 2013 Q2 | -355 Thousand SEK | -150.43% |
| 2013 Q1 | 704 Thousand SEK | 116.96% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q3 | -2.71 Million SEK | 0.0% |
| 2012 Q4 | -4.15 Million SEK | -53.06% |
| 2012 FY | -11.86 Million SEK | -313.46% |
| 2012 Q1 | - SEK | -100.0% |
| 2011 Q2 | 2.7 Million SEK | 88.88% |
| 2011 Q4 | 556.46 Thousand SEK | -36.02% |
| 2011 FY | 5.55 Million SEK | 60.91% |
| 2011 Q1 | 1.42 Million SEK | 54.04% |
| 2011 Q3 | 869.8 Thousand SEK | -67.79% |
| 2010 Q3 | 1.7 Million SEK | 290.86% |
| 2010 Q1 | 386.45 Thousand SEK | -76.7% |
| 2010 Q4 | 928.01 Thousand SEK | -45.5% |
| 2010 FY | 3.45 Million SEK | -22.11% |
| 2010 Q2 | 435.62 Thousand SEK | 12.72% |
| 2009 Q2 | 909.98 Thousand SEK | 38.74% |
| 2009 Q3 | 1.2 Million SEK | 32.75% |
| 2009 Q4 | 1.65 Million SEK | 37.31% |
| 2009 FY | 4.43 Million SEK | 387.83% |
| 2009 Q1 | 655.9 Thousand SEK | 0.0% |
| 2008 FY | 908.66 Thousand SEK | 0.0% |
| 2007 FY | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 77.806% |
| Ziccum AB (publ) | -23.28 Million SEK | -53.152% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 110.298% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 185.345% |
| Mendus AB (publ) | 28.48 Million SEK | 225.19% |
| Genovis AB (publ.) | 54 Million SEK | 166.041% |
| Intervacc AB (publ) | -13.79 Million SEK | -158.54% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 1742.699% |
| Active Biotech AB (publ) | -1.67 Million SEK | -2029.134% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 457.954% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 232.967% |
| Aptahem AB (publ) | 2.63 Million SEK | 1455.674% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -942.473% |
| Kancera AB (publ) | -1.96 Million SEK | -1714.911% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 46415.584% |
| Fluicell AB (publ) | 1.73 Million SEK | 2151.956% |
| Saniona AB (publ) | 11.78 Million SEK | 402.716% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | -596.951% |
| Biovica International AB (publ) | 6.87 Million SEK | 618.584% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | -53.172% |
| AcouSort AB (publ) | 8.38 Million SEK | 525.116% |
| Xintela AB (publ) | 78 Thousand SEK | 45821.795% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 75.723% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 1370.502% |
| OncoZenge AB (publ) | 3000.00 SEK | 1188866.667% |
| Amniotics AB (publ) | -1.93 Million SEK | -1747.824% |
| 2cureX AB (publ) | -37.48 Million SEK | 4.866% |
| CombiGene AB (publ) | -21.29 Million SEK | -67.505% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -8330.969% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 103.156% |
| Camurus AB (publ) | 1.58 Billion SEK | 102.256% |
| Corline Biomedical AB | 28.38 Million SEK | 225.662% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 70.943% |
| Isofol Medical AB (publ) | -34.41 Million SEK | -3.626% |
| I-Tech AB | 27.56 Million SEK | 229.373% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 150.264% |
| Cyxone AB (publ) | 2.61 Million SEK | 1465.875% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 1147.987% |
| Biosergen AB | -456 Thousand SEK | -7720.833% |
| Cantargia AB (publ) | -3.45 Million SEK | -933.411% |
| NextCell Pharma AB | -43.74 Million SEK | 18.481% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | -287.894% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 417.901% |
| Nanologica AB (publ) | -76 Thousand SEK | -46825.0% |
| SynAct Pharma AB | -778 Thousand SEK | -4483.933% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -18378.238% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | -175.987% |
| Lipum AB (publ) | 53 Thousand SEK | 67388.679% |
| BioInvent International AB (publ) | 71.46 Million SEK | 149.906% |
| Alzinova AB (publ) | 19.87 Million SEK | 279.446% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 198.248% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 2537.629% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -237653.333% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 2250.965% |
| Simris Alg AB (publ) | 2 Million SEK | 1876.931% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | -896.173% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 200.777% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -3299.714% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 1238.302% |